{"id":2225,"date":"2007-09-03T14:43:11","date_gmt":"2007-09-03T13:43:11","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2225"},"modified":"2013-09-12T16:51:51","modified_gmt":"2013-09-12T16:51:51","slug":"fosamprenavirr-vs-atazanvirr-in-treatment-naive-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2225","title":{"rendered":"Fosamprenavir\/r vs atazanvir\/r in treatment-naive patients"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Keith Pappa presented 48 week results from a GSK study in 106 treatment-naive patients randomised to either fosamprenavir\/r (1400mg\/100mg QD) or atazanavir\/r (300mg\/100mg QD), both with tenofovir plus FTC backbone.<\/strong><\/p>\n<p>While the study was not powered for a difference between these two arms, the atazanavir group showed greater suppression to both &lt;400 copies\/mL (87 vs 79%) and for the primary endpoint of suppression to &lt;50 copies\/mL (83% vs 75%).<\/p>\n<p>Lipid increases from baseline included: total cholesterol +11 vs + 27 mg\/dL; triglycerides +34 vs +6 mg\/dL; LDL +4 vs +4 mg\/dL; and HDL +5 vs +11 mg\/dL in the fosamprenavir\/r and atazanavir\/r arms respectively.<\/p>\n<h3>Comment<\/h3>\n<p class=\"comment\"><strong>Whatever the power of the study, (p-values for the statistical virological difference between the two arms was p=0.3), these results do not appear to show any benefit of using fosamprenavir over atazanavir.<\/strong><\/p>\n<p class=\"ref\">Reference:<\/p>\n<p class=\"ref\">Smith K, Weinberg W, DeJesus E et al. Once-daily ritonavir (100mg) boosting of fosamprenavir (FPV\/r) or atazanavir (ATZ\/r) withtenofovir(TDF)\/emtricitabine(FTC) in antiretroviral-naive HIV-infected patients: 48-week safety\/efficacy results from COL103952 (ALERT). 4thIAS 2007. Abstract WEPEB023. <a href=\"http:\/\/www.ias2007.org\/pag\/Abstracts.aspx?AID=155&amp;AID=1208\"><br \/>\nhttp:\/\/www.ias2007.org\/pag\/Abstracts.aspx?AID=155&amp;AID=1208<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Keith Pappa presented 48 week results from a GSK study in 106 treatment-naive patients randomised to either fosamprenavir\/r (1400mg\/100mg QD) or atazanavir\/r (300mg\/100mg QD), both with tenofovir plus FTC backbone. While the study was not powered &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[92],"class_list":["post-2225","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-ias-4th-2007"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2225"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2225\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}